These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 11054093)

  • 21. Iron chelators for thalassaemia.
    Hershko C; Konijn AM; Link G
    Br J Haematol; 1998 Jun; 101(3):399-406. PubMed ID: 9633877
    [No Abstract]   [Full Text] [Related]  

  • 22. Retrospective study on the combination of desferrioxamine and deferasirox for treatment of iron-overloaded thalassemic patients: first evidence of more than 2 years.
    Jetsrisuparb A; Komvilaisak P; Wiangnon S; Jetsrisuparb C
    J Pediatr Hematol Oncol; 2010 Jul; 32(5):400-3. PubMed ID: 20505533
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Combination therapy of deferasirox and deferoxamine shows significant improvements in markers of iron overload in a patient with β-thalassemia major and severe iron burden.
    Voskaridou E; Komninaka V; Karavas A; Terpos E; Akianidis V; Christoulas D
    Transfusion; 2014 Mar; 54(3):646-9. PubMed ID: 23834310
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Increased serum hepcidin levels during treatment with deferasirox in iron-overloaded patients with myelodysplastic syndrome.
    Ghoti H; Fibach E; Westerman M; Gordana O; Ganz T; Rachmilewitz EA
    Br J Haematol; 2011 Apr; 153(1):118-20. PubMed ID: 21332711
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The role of iron and chelators on infections in iron overload and non iron loaded conditions: prospects for the design of new antimicrobial therapies.
    Kontoghiorghes GJ; Kolnagou A; Skiada A; Petrikkos G
    Hemoglobin; 2010 Jun; 34(3):227-39. PubMed ID: 20524813
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Deferasirox pharmacokinetic evaluation in β-thalassaemia paediatric patients.
    Allegra S; Cusato J; De Francia S; Pirro E; Massano D; Piga A; D'Avolio A
    J Pharm Pharmacol; 2017 May; 69(5):525-528. PubMed ID: 27230486
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Efficacy and safety of deferasirox in β-thalassemia major patients in Iran: a prospective study from a single referral center in Iran.
    Alavi S; Ebadi M; Ghazizadeh F; Arzanian MT; Shamsian B; Abdollah Gorji F
    Pediatr Hematol Oncol; 2014 Feb; 31(1):76-86. PubMed ID: 24383712
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Combined Iron Chelator and Antioxidant Exerted Greater Efficacy on Cardioprotection Than Monotherapy in Iron-Overloaded Rats.
    Wongjaikam S; Kumfu S; Khamseekaew J; Sripetchwandee J; Srichairatanakool S; Fucharoen S; Chattipakorn SC; Chattipakorn N
    PLoS One; 2016; 11(7):e0159414. PubMed ID: 27428732
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Deferasirox: An effective once-daily orally active iron chelator.
    Porter JB
    Drugs Today (Barc); 2006 Oct; 42(10):623-37. PubMed ID: 17136223
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Deferasirox protects against iron-induced hepatic injury in Mongolian gerbil.
    Al-Rousan RM; Rice KM; Katta A; Laurino J; Walker EM; Wu M; Triest WE; Blough ER
    Transl Res; 2011 Jun; 157(6):368-77. PubMed ID: 21575921
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Deferasirox--an oral agent for chronic iron overload.
    Vanorden HE; Hagemann TM
    Ann Pharmacother; 2006 Jun; 40(6):1110-7. PubMed ID: 16735647
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Efficacy and safety of iron-chelation therapy with deferoxamine, deferiprone, and deferasirox for the treatment of iron-loaded patients with non-transfusion-dependent thalassemia syndromes.
    Kontoghiorghe CN; Kontoghiorghes GJ
    Drug Des Devel Ther; 2016; 10():465-81. PubMed ID: 26893541
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Cost effectiveness of deferasirox compared to desferrioxamine in the treatment of iron overload in lower-risk, transfusion-dependent myelodysplastic syndrome patients.
    Tolley K; Oliver N; Miranda E; Migliaccio-Walle K; Bozkaya D; Li Q
    J Med Econ; 2010; 13(3):559-70. PubMed ID: 20812793
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The oral chelator deferasirox--a new perspective for patients with iron overload.
    Fischer R
    Haematologica; 2006 Jul; 91(7):865A. PubMed ID: 16818263
    [No Abstract]   [Full Text] [Related]  

  • 35. The effects of deferasirox on renal, cardiac and hepatic iron load in patients with β-thalassemia major: preliminary results.
    Unal S; Hazirolan T; Eldem G; Gumruk F
    Pediatr Hematol Oncol; 2011 Apr; 28(3):217-21. PubMed ID: 21083355
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Combination of deferasirox and deferoxamine in clinical practice: an alternative scheme of chelation in thalassemia major patients.
    Cassinerio E; Orofino N; Roghi A; Duca L; Poggiali E; Fraquelli M; Zanaboni L; Cappellini MD
    Blood Cells Mol Dis; 2014 Sep; 53(3):164-7. PubMed ID: 24846580
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Deferasirox for the treatment of chronic iron overload in transfusional hemosiderosis.
    Shashaty G; Frankewich R; Chakraborti T; Choudary J; Al-Fayoumi S; Kacuba A; Castillo S; Robie-Suh K; Rieves D; Weiss K; Pazdur R
    Oncology (Williston Park); 2006 Dec; 20(14):1799-1806, 1811; discussion 1811-13, 1817. PubMed ID: 17263129
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Deferasirox removes cardiac iron and attenuates oxidative stress in the iron-overloaded gerbil.
    Al-Rousan RM; Paturi S; Laurino JP; Kakarla SK; Gutta AK; Walker EM; Blough ER
    Am J Hematol; 2009 Sep; 84(9):565-70. PubMed ID: 19650117
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Deferasirox (Exjade): a new iron chelator.
    Med Lett Drugs Ther; 2006 Apr; 48(1233):35-6. PubMed ID: 16625144
    [No Abstract]   [Full Text] [Related]  

  • 40. Aceruloplasminaemia: a family with a novel mutation and long-term therapy with deferasirox.
    Lindner U; Schuppan D; Schleithoff L; Habeck JO; Grodde T; Kirchhof K; Stoelzel U
    Horm Metab Res; 2015 Apr; 47(4):303-8. PubMed ID: 25089372
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.